Autres langues H. Lundbeck A/S

Actions

HLUN B

DK0061804770

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 22/04/2025			Varia. 5j.	Varia. 1 janv.
27,54 ^DKK	-3,57%		-3,97%	-33,35%

08/04	Barclays abaisse le prix cible de Lundbeck à 46 (48) DKK et réitère sa pondération égale - BN	FW
04/04	Lundbeck présentera des données positives sur son pipeline à l'AAN	FW

Autres langues

H Lundbeck A/S : Articles of Association (HLU Articles of Association 2025)	09/04
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting	04/04
H. Lundbeck A/S to Present Positive Pipeline Data At American Academy of Neurology Annual Meeting	04/04
Lundbeck to Expand Phase 2b Trial for Migraine Prevention Therapy	31/03
Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention	31/03
H. Lundbeck A/S Expands the Dose Findings to Intravenous Administration of Lu AG09222 in Migraine Prevention	31/03
H Lundbeck A/S : Presentation (AGM Presentation 2025 03 26)	26/03
Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office	26/03
H. Lundbeck A/S Approves to Distribute Dividend for the Year 2024	26/03
H. Lundbeck A/S Appoints Lars Green as Member of Board of Directors and Member of Audit Committee	26/03
H. Lundbeck Wins EU Nod for Schizophrenia Drug Use in Adolescents	13/03
Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older	13/03
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Approves Rxulti®? (Brexpiprazole) for the Treatment of Schizophrenia	13/03
H. Lundbeck's Amlenetug Wins Orphan Drug Designation in Japan	10/03
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan	10/03
H Lundbeck A/S : NOTICE OF ANNUAL GENERAL MEETING (NOTICE OF ANNUAL GENERAL MEETING)	25/02
H Lundbeck A/S : Registration Form (Registration Form)	25/02
H Lundbeck A/S : Proxy and postal vote form (Proxy and postal vote form)	25/02
H Lundbeck A/S : Appendix 1 Remuneration Policy (Appendix 1 Remuneration Policy)	25/02
To the shareholders of H. Lundbeck A/S	25/02
H Lundbeck A/S : Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	21/02
H. Lundbeck's Multiple System Atrophy Drug Gets US FDA Fast-track Status	12/02
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA	12/02
H. Lundbeck A/S Receives Fast Track Designation from United States Food and Drug Administration	12/02
H LUNDBECK : Healthy Q4; recent correction should be capitalized as entry/accumulation opportunity	07/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

H LUNDBECK : T4 sain ; la récente correction devrait être considérée comme une opportunité d'entrée/accumulation

Le 07 février 2025 à 15:22

Lundbeck : possible rebond compte tenu des perspectives

Le 19 novembre 2024 à 18:13